Regeneron Pharmaceuticals (NASDAQ:REGN) Now Covered by Analysts at Piper Sandler

Stock analysts at Piper Sandler initiated coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note issued on Tuesday. The brokerage set an “overweight” rating and a $875.00 price target on the biopharmaceutical company’s stock. Piper Sandler’s price objective points to a potential upside of 16.78% from the stock’s previous close.

Several other research analysts also recently issued reports on REGN. Oppenheimer restated an “outperform” rating and set a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a report on Monday, February 2nd. Cantor Fitzgerald lifted their target price on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Wells Fargo & Company boosted their price target on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the company an “equal weight” rating in a research note on Monday, February 2nd. Truist Financial cut their price target on Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a report on Monday, February 2nd. Finally, Royal Bank Of Canada raised their price objective on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the stock a “sector perform” rating in a research report on Monday, March 2nd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $805.43.

Regeneron Pharmaceuticals Stock Up 1.6%

REGN opened at $749.29 on Tuesday. The business has a 50 day moving average of $765.00 and a 200-day moving average of $709.34. The stock has a market capitalization of $79.21 billion, a price-to-earnings ratio of 18.03, a P/E/G ratio of 1.98 and a beta of 0.40. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 1-year low of $476.49 and a 1-year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The business had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. Regeneron Pharmaceuticals’s revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $12.07 earnings per share. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,330,604.99. This represents a 49.03% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. This trade represents a 46.83% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 5,274 shares of company stock valued at $4,142,738. 7.02% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in REGN. Brighton Jones LLC lifted its holdings in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after purchasing an additional 686 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Regeneron Pharmaceuticals during the first quarter worth about $226,000. J.W. Cole Advisors Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 3.5% during the second quarter. J.W. Cole Advisors Inc. now owns 997 shares of the biopharmaceutical company’s stock worth $523,000 after buying an additional 34 shares in the last quarter. Elevation Point Wealth Partners LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $59,000. Finally, Lido Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 34.8% in the second quarter. Lido Advisors LLC now owns 5,672 shares of the biopharmaceutical company’s stock valued at $2,978,000 after acquiring an additional 1,464 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.